Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics Inc (FULC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 452,481
  • Shares Outstanding, K 62,154
  • Annual Sales, $ 2,810 K
  • Annual Income, $ -97,340 K
  • 60-Month Beta 2.29
  • Price/Sales 164.86
  • Price/Cash Flow N/A
  • Price/Book 1.91
Trade FULC with:

Options Overview Details

View History
  • Implied Volatility 109.74% ( -1.79%)
  • Historical Volatility 49.21%
  • IV Percentile 80%
  • IV Rank 28.88%
  • IV High 309.23% on 06/22/23
  • IV Low 28.73% on 01/22/24
  • Put/Call Vol Ratio 0.45
  • Today's Volume 279
  • Volume Avg (30-Day) 1,362
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 62,050
  • Open Int (30-Day) 53,445

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.44
  • Number of Estimates 6
  • High Estimate -0.40
  • Low Estimate -0.46
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -7.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.67 +6.90%
on 04/19/24
9.81 -27.32%
on 03/26/24
-2.30 (-24.39%)
since 03/25/24
3-Month
6.67 +6.90%
on 04/19/24
13.70 -47.96%
on 03/06/24
+0.13 (+1.86%)
since 01/25/24
52-Week
2.43 +193.42%
on 05/01/23
13.70 -47.96%
on 03/06/24
+4.53 (+174.23%)
since 04/25/23

Most Recent Stories

More News
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when...

ONCY : 1.0800 (+1.89%)
ONC.TO : 1.49 (+1.36%)
FULC : 7.13 (-2.06%)
RNA : 23.83 (-5.02%)
BCTX : 2.24 (+2.28%)
BCT.TO : 3.01 (+0.33%)
GILD : 65.27 (-2.70%)
FULC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2023 in the Class Action Filed on Behalf of Fulcrum Therapeutics, Inc. Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fulcrum Therapeutics, Inc. (NASDAQ:...

FULC : 7.13 (-2.06%)
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fulcrum Investors of a Lead Plaintiff Deadline of June 27, 2023

/PRNewswire/ -- Attention Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) shareholders: The Law Offices of Vincent Wong announce that a class action...

FULC : 7.13 (-2.06%)
FULC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between...

FULC : 7.13 (-2.06%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fulcrum Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FULC

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ:...

FULC : 7.13 (-2.06%)
FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action...

FULC : 7.13 (-2.06%)
FULC SHAREHOLDER ALERT: Jakubowitz Law Reminds Fulcrum Shareholders of a Lead Plaintiff Deadline of June 27, 2023

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fulcrum Therapeutics, Inc....

FULC : 7.13 (-2.06%)
FULC LAWSUIT ALERT: Levi & Korsinsky Notifies Fulcrum Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC) of a class action securities...

FULC : 7.13 (-2.06%)
FULC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2023 in the Class Action Filed on Behalf of Fulcrum Therapeutics, Inc. Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fulcrum Therapeutics, Inc. (NASDAQ:...

FULC : 7.13 (-2.06%)
FULC Investors Have Opportunity to Lead Fulcrum Therapeutics, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...

FULC : 7.13 (-2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 7.59
2nd Resistance Point 7.38
1st Resistance Point 7.26
Last Price 7.13
1st Support Level 6.93
2nd Support Level 6.72
3rd Support Level 6.60

See More

52-Week High 13.70
Fibonacci 61.8% 9.39
Fibonacci 50% 8.06
Last Price 7.13
Fibonacci 38.2% 6.74
52-Week Low 2.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar